Menopausal hormone replacement therapy and risk of ovarian cancer.

By J. Lacey, P. Mink, J. Lubin, M. Sherman, R. Troisi, P. Hartge, A. Schatzkin, C. Schairer. Journal of the American Medical Association (JAMA), 2002

618 citations recorded by the source corpus.

Subfields: Genetics, Obstetrics and Gynecology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/ce7d77faa5db3824a5af73edbba2dc0be75ed9a0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. L. Al-Nakkash
2. Melissa M. Herbst-Kralovetz
3. James M Baker

Citations in the corpus

• Estrogen-gut microbiome axis: Physiological and clinical implications. (2017, background): “Estrogen has been associated with a variety of sex-hormone driven cancers including: endometrial [12], cervical [68], ovarian [69], prostate [70] and breast cancer [71].”
• Ovarian cancer in the world: epidemiology and risk factors (2019, neutral): “Researchers believe that the use of estrogenic methods, especially for 10 years or more, is associated with an increased risk of ovarian cancer.(94) The result of”